Avalon GloboCare Corp. CEO David Jin, M.D., Ph.D. to Present and Chair the "China's Impact on The World of Regenerative Medicine" Session at the 13th Annual World Stem Cell Summit

FREEHOLD, NJ--(Marketwired - January 21, 2018) - Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies, announced today that President and Chief Executive Officer David Jin, M.D., Ph.D. will chair a session entitled, "China's impact on the world of regenerative medicine," and provide a keynote presentation at the 13th Annual World Stem Cell Summit in Miami, Florida.

Session information:

Date: January 24, 2018

Time: 2:15 p.m. ET

Venue: Hyatt Regency Miami

"Avalon GloboCare is dedicated to integrating the premier scientific, clinical, regulatory, and investment resources from around the world, to promote and foster precision and regenerative medicine," stated Dr. David Jin. "We are honored to lead a China panel, representing leading experts in an evolving regenerative medicine ecosystem. We look forward to sharing our respective experience and capabilities in cell-based therapeutics," added Dr. Jin.

The 2018 World Stem Cell Summit is the global, super-ecosystem event, trans-disciplinary in scope. The Summit is designed to breakdown silos, expand scientific/clinical knowledge and forge collaborations, with the overarching collective goal to improve health and deliver cures. For more information please visit http://www.worldstemcellsummit.com/.

About Avalon GloboCare Corp.

Avalon GloboCare Corp. (OTCQB: AVCO) is a global intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high impact, transformative cell-based technologies and their clinical applications, as well as healthcare facility management through its core platforms, namely "Avalon Cell" and "Avalon Rehab." In addition, Avalon provides strategic advisory and outsourcing services to facilitate and enhance their clients' growth, development, as well as competitiveness in both domestic and global healthcare markets. Avalon also engages in the management of stem cell banks and specialty clinical laboratories. Through its U.S. subsidiary, GenExosome Technologies Inc., Avalon further establishes its leading role in the fields of liquid biopsy, precision medicine and regenerative medicine.

About the World Stem Cell Summit

Produced by the 501(c)(3) non-profit Regenerative Medicine Foundation (RMF), and in its 13th year, the World Stem Cell Summit 2018 is co-located with the Phacilitate Leadership Forum, Cell & Gene Therapy World and Immuno-Oncology Frontiers World conferences. It is the most inclusive and expansive interdisciplinary, networking, and partnering meeting in the stem cell science and regenerative medicine field. With the overarching purpose of fostering biomedical research, funding, and investments targeting cures, the Summit is the single conference serving the diverse ecosystem of stakeholders.

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.